Connie A Haley, Marcos C Schechter, David Ashkin, Charles A Peloquin, J Peter Cegielski, Barbara B Andrino, Marcos Burgos, Lori A Caloia, Lisa Chen, Angel Colon-Semidey, Malini B DeSilva, Shireesha Dhanireddy, Susan E Dorman, Felicia F Dworkin, Heidi Hammond-Epstein, Alice V Easton, James T Gaensbauer, Bijan Ghassemieh, Maria E Gomez, David Horne, Supriya Jasuja, Betsy A Jones, Leonard J Kaplan, Asharaf Edward Khan, Elizabeth Kracen, Sarah Labuda, Karen M Landers, Alfred A Lardizabal, Maria T Lasley, David M Letzer, Vinicius K Lopes, Ronald J Lubelchek, C Patricia Macias, Aimee Mihalyov, Elizabeth Ann Misch, Jason A Murray, Masahiro Narita, Diana M Nilsen, Megan J Ninneman, Lynne Ogawa, Alawode Oladele, Melissa Overman, Susan M Ray, Kathleen A Ritger, Marie-Claire Rowlinson, Nadya Sabuwala, Thomas M Schiller, Lawrence E Schwartz, Christopher Spitters, Douglas B Thomson, Rene Rico Tresgallo, Patrick Valois, Neela D Goswami
BACKGROUND: Rifampin-resistant tuberculosis is a leading cause of morbidity worldwide; only one-third of persons initiate treatment and outcomes are often inadequate. Several trials demonstrate 90% efficacy using an all-oral, six-month regimen of bedaquiline, pretomanid, and linezolid (BPaL), but significant toxicity occurred using 1200 mg linezolid. After U.S. FDA approval in 2019, some U.S. clinicians rapidly implemented BPaL using an initial linezolid 600 mg dose adjusted by serum drug concentrations and clinical monitoring...
May 30, 2023: Clinical Infectious Diseases